The clinical application of linagliptin in Asians

被引：5

作者：

Cao, Chu-qing ^{[1
]}

Xiang, Yu-fei ^{[1
]}

Zhou, Zhi-guang ^{[1
]}

机构：

[1] Cent S Univ, Key Lab Diabet Immunol, Minist Educ,Xiangya Hosp 2, Natl Clin Res Ctr Metab Dis,Inst Metab & Endocrin, Changsha 410011, Hunan, Peoples R China

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2015年 / 11卷

基金：

中国国家自然科学基金;

关键词：

linagliptin; Asians; type; 2; diabetes; TYPE-2; DIABETES-MELLITUS; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ADD-ON THERAPY; IMPROVES GLYCEMIC CONTROL; INCRETIN-BASED THERAPIES; DOUBLE-BLIND; JAPANESE PATIENTS; CHINESE PATIENTS; RENAL IMPAIRMENT; DPP-4; INHIBITION;

D O I：

10.2147/TCRM.S64402

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Asia has a growing diabetic population. Linagliptin, a member of dipeptidyl peptidase-4 inhibitor class, is unique in its nonlinear pharmacokinetics with the characteristics of rapid attainment of steady state, little accumulation, predominantly nonrenal route of elimination, prolonged terminal half-life, and sustained inhibition of dipeptidyl peptidase-4 enzyme. No clinically relevant difference in pharmacokinetics was observed between Asians and non-Asians. The management of type 2 diabetes is increasingly challenging with the progression of disease, especially with the requirements of minimal hypoglycemia, weight gain, fluid retention, and other adverse effects. Linagliptin was efficacious and well-tolerated in Asian type 2 diabetes patients with or without renal or hepatic dysfunctions, comparable to that in Caucasians. This review will focus on the usage of linagliptin in clinical studies in Asians.

引用

页码：1409 / 1419

页数：11

共 70 条

[21] Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges [J].

Ghazi, Tara ;

Rink, Linda ;

Sherr, Jennifer L. ;

Herold, Kevan C. .

DIABETES CARE, 2014, 37 (01) :210-216

[22] Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study [J].

Gomis, R. ;

Espadero, R. -M. ;

Jones, R. ;

Woerle, H. J. ;

Dugi, K. A. .

DIABETES OBESITY & METABOLISM, 2011, 13 (07) :653-661

[23] Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin [J].

Graefe-Mody, U. ;

Friedrich, C. ;

Port, A. ;

Ring, A. ;

Retlich, S. ;

Heise, T. ;

Halabi, A. ;

Woerle, H. -J. .

DIABETES OBESITY & METABOLISM, 2011, 13 (10) :939-946

[24] Pharmacokinetics of linagliptin in subjects with hepatic impairment [J].

Graefe-Mody, Ulrike ;

Rose, Peter ;

Retlich, Silke ;

Ring, Arne ;

Waldhauser, Lisa ;

Cinca, Rodica ;

Woerle, Hans-Juergen .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (01) :75-85

[25] Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction [J].

Groop, Per-Henrik ;

Cooper, Mark E. ;

Perkovic, Vlado ;

Emser, Angela ;

Woerle, Hans-Juergen ;

von Eynatten, Maximilian .

DIABETES CARE, 2013, 36 (11) :3460-3468

[26] Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations [J].

Gujral, Unjali P. ;

Pradeepa, R. ;

Weber, Mary Beth ;

Narayan, K. M. Venkat ;

Mohan, V. .

YEAR IN DIABETES AND OBESITY, 2013, 1281 :51-63

[27] Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study [J].

Haak, T. ;

Meinicke, T. ;

Jones, R. ;

Weber, S. ;

von Eynatten, M. ;

Woerle, H. -J. .

DIABETES OBESITY & METABOLISM, 2012, 14 (06) :565-574

[28] Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients [J].

Heise, T. ;

Graefe-Mody, E. U. ;

Huettner, S. ;

Ring, A. ;

Trommeshauser, D. ;

Dugi, K. A. .

DIABETES OBESITY & METABOLISM, 2009, 11 (08) :786-794

[29] Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses [J].

Herman, GA ;

Stevens, C ;

Van Dyck, K ;

Bergman, A ;

Yi, BM ;

De Smet, M ;

Snyder, E ;

Hilliard, D ;

Tanen, M ;

Tanaka, W ;

Wang, AQ ;

Zeng, W ;

Musson, D ;

Winchell, G ;

Davies, MJ ;

Ramael, S ;

Gottesdiener, KM ;

Wagner, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :675-688

[30] Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients [J].

Horie, Yoshiharu ;

Kanada, Shigeto ;

Watada, Hirotaka ;

Sarashina, Akiko ;

Taniguchi, Atsushi ;

Hayashi, Naoyuki ;

Graefe-Mody, Eva U. ;

Woerle, Hans-Juergen ;

Dugi, Klaus A. .

CLINICAL THERAPEUTICS, 2011, 33 (07) :973-989

← 1 2 3 4 5 6 7 →